Lyka Labs Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Kunal Gandhi & PACs, was filed 22 Jul 2026.
Lyka Labs Limited: what insiders have been doing
Every trade that managers of Lyka Labs Limited disclose to SEBI (PIT + SAST) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 26 October 2026, 4 filings were filed, from 3 insiders.
Every open-market trade in the period is a purchase: 4 purchases worth €9,505, from 3 insiders, and not a single sale. The totals do not cover 2 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 3 major shareholders. The largest single trade was a purchase of €8,654 by Kunal N Gandhi, published on 30 June 2026, equal to 0.031% of the market capitalisation.
The clock since the last published purchase (22 July 2026) now reads 109 days. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. That lag is the time during which only the insider knows about the trade.
Compared with its exchange (1,891 companies, median 4 filings), a count of 4 filings is typical. Our records for Lyka Labs Limited go back to 2022, with 4 purchases and no sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEBI (PIT + SAST). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- +9.1%Entry ₹74.21 · Close 23 Oct 2026 ₹80.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 55,967 shares-MarketSEBI:bfda38d03e194d150d17ea3c4b6117d7e84ef674Canonical exit: 20 Oct 2026 (T+90)
- 14,176 shares-MarketSEBI:b6927509c8cb64635fa13e23b0225fd8ea9a91bbCanonical exit: 20 Oct 2026 (T+90)
- 12,914 shares@ ₹72.500.031% mcap91.1% of flowEquity SharesMarket PurchaseSEBI:ab269508cd568e2fe6f516130e8f987dce0e4759Canonical exit: 28 Sept 2026 (T+90)
- 1,262 shares@ ₹72.900.0030% mcap8.9% of flowEquity SharesMarket PurchaseSEBI:c6f88c7a38aeca9bb1217337b565ffd6b7805be3Canonical exit: 28 Sept 2026 (T+90)
- 2,600,000 shares@ ₹139.5021.6% of flowEquity SharesSEBI:5b972d34b6d36afd06378a6499cb2efa13044026
- 53,000 sharesEquity SharesSEBI:5f823ba32d01cff1253e405bab30372779dbde95
- 1,500 sharesEquity SharesSEBI:96874fd61ce563fbf14f92416567aebd6278639e
- 900 sharesEquity SharesSEBI:1aaf959aea14659c3fc77a524965c0c6a227cba8
- 4,600 sharesEquity SharesSEBI:f8a3ca21a05e015c2ad502e863f219b8a81cb3d3
- 1,350,000 sharesEquity SharesSEBI:21ea5d24a327d961efe64f3a0aaa0d65b6742a11
- 1,350,000 sharesEquity SharesSEBI:0b5e75193a958cdfd558080c137e8f8067b2ea9f
- 2,400,000 shares@ ₹139.5019.7% of flowEquity SharesSEBI:8637f3e45daa8e5b8a1150a70d884c9f1de99054
- 634,429 sharesEquity SharesSEBI:b5b066bedd6a4e0bcfe018065bed27cc5a971424
- 634,429 sharesEquity SharesSEBI:8b62fc1c72c93597579fcf18894a1302946e02eb
- 148,000 sharesEquity SharesSEBI:75cb9cf7492b19dc88c0b816c8ccc065b3e710d4
- 148,000 sharesEquity SharesSEBI:0496424aa0c1e3f150fb5509f0cc354c6ce1bbf0
- 385,200 sharesEquity SharesSEBI:dc075530e894158d6c5c22c86ba397d6193af83c
- 2,000,000 shares@ ₹139.5016.8% of flowEquity SharesSEBI:4a3e7510b98d55755b5491b267f575af08a8aed6
- 5,000,000 shares@ ₹139.5041.9% of flowWarrantsSEBI:4d56f13ec5b82fde5629ca4bf6c2e391c04d5e05
- 50,776 sharesEquity SharesSEBI:66eea61989a7a0904a8b0a6d3c0b5bea36fa734d
- 50,776 sharesEquity SharesSEBI:cd7f9d97d24d8b645986e059eb77170ecf77ffad
- 0Equity SharesSEBI:9c45e700f4a69a4dd70d2531fe7fea972ce248cc
- 0Equity SharesSEBI:6a2c38210edccf2e8346105a28a50ce7db2cefb1
- 781 shares@ ₹130.50060.0% of flowEquity SharesSEBI:5ad356359be155ce0e4f586dc066f504ad889ea4
- 0Equity SharesSEBI:67053dac883275daaab01094f9f99b91218e9ad2
25 of 27 declarations
About Lyka Labs Limited
Lyka Labs Limited is a company operating in the health and pharmaceutical sector, specializing in the development of innovative solutions. It is listed on the XBOM.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
